Drug General Information (ID: DDIQ79IGB8)
Drug Name			Abarelix		Drug Info		Ivabradine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Cardiovascular Agents
Structure

Mechanism of Abarelix-Ivabradine Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Abarelix				Ivabradine
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Abarelix and Ivabradine

Recommended Action
Management		Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided. Caution and cardiac monitoring are recommended if concomitant use is required.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Mittal SR "Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine." J Assoc Physicians India 62 (2014): 426-7. [PMID: 25438492]
3	Product Information. Corlanor (ivabradine). Amgen USA, Thousand Oaks, CA.